Clik here to view.
Riverain Receives $15 Million Growth Capital Investment
MIAMISBURG, Ohio Riverain Technologies, a leading provider of clinical artificial intelligence software used to efficiently detect lung disease at its earliest stages, has received a $15 million...
View ArticleClik here to view.
Solasia宣布，Darinaparsin治疗T细胞淋巴瘤2期枢纽性研究患者登记达到目标病例数
东京 (美国商业资讯)–Solasia Pharma K.K.（TSE:4597，总部：东京，总裁兼首席执行官：Yoshihiro Arai，以下简称“Solasia”）是一家总部位于亚洲的专科制药公司。该公司今天宣布，darinaparsin 2期研究患者登记达到目标病例数。...
View ArticleClik here to view.
Shionogi to Present New Data at IDWeek 2019
OSAKA, Japan & FLORHAM PARK, N.J. Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced that the company will deliver 20 data presentations for Shionogi compounds, including a...
View ArticleClik here to view.
Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference...
View ArticleClik here to view.
Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib...
WILMINGTON, Del. Incyte (Nasdaq:INCY) announces updated results, including the final result for the primary endpoint, from its Phase 2 FIGHT-202 trial evaluating pemigatinib, a selective fibroblast...
View ArticleClik here to view.
CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase...
WILMINGTON, Del. Sixth paragraph, fourth sentence of release should read: Serous retinal detachment was observed in 4 percent of patients (Grade ≥3, 1 percent) with none of the cases resulting in...
View ArticleClik here to view.
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of...
TOKYO & BOTHELL, Wash. Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced initial results from the...
View ArticleClik here to view.
三叶草生物制药在研1类新药SCB-313中国恶性腹水I期临床完成首例患者给药
成都 (美国商业资讯)–三叶草生物制药，一家致力于创新及变革性生物药物研发的生物制药公司，今天宣布在中国进行的另一项SCB-313 I期临床试验完成首例患者给药。SCB-313是一种创新重组人肿瘤坏死因子相关凋亡诱导配体（TRAIL）-...
View ArticleClik here to view.
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in...
CHENGDU, China Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in another Phase...
View ArticleClik here to view.
NMPA Approves IND Application for CT103A, a Fully-human BCMA CAR-T for the...
NANJING, China IASO Biotherapeutics (IASO BIO), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, and Innovent Biologics, Inc. (Innovent)...
View ArticleClik here to view.
Agilent Receives Approval for First PD-L1 Companion Diagnostic in China
SANTA CLARA, Calif. Agilent Technologies Inc. (NYSE: A) today announced that the National Medical Products Administration (NMPA, formerly the China Food and Drug Administration) has approved its...
View ArticleClik here to view.
ザ エスティ ローダー カンパニーズ、2019年の乳がんキャンペーンで願いを込めて世界をつなぐ
ニューヨーク （ビジネスワイヤ） — 世界のどこかで15秒ごとに1人の女性が乳がんと診断されています1。そのため、1992年より、ザ エスティ ローダー カンパニーズは、乳がんのない世界を目指す乳がんキャンペーンにおいて、あらゆる地域の人々を結集させてプラスの影響を及ぼし、命を救うことに取り組んできました。27年にわたり、ザ エスティ ローダー...
View ArticleClik here to view.
MPEG LA、査読論文のNucleic Acid Therapeutics誌への掲載を発表
デンバー （ビジネスワイヤ） — 技術ライセンシングの世界的リーダー企業MPEG LAは本日、Nucleic Acid Therapeutics誌の2019年10月号に、MPEG LA専有のリガンド指向型多重ペイロード・オリゴヌクレオチド送達プラットフォームIncrescent Therapeutics™に関する査読論文が掲載されたと発表しました。 MPEG...
View ArticleClik here to view.
Clik here to view.
GRAIL Announces Positive Validation Data for Its Multi-Cancer Early Detection...
MENLO PARK, Calif. GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced new data validating the performance of its investigational multi-cancer early detection...
View ArticleClik here to view.
CORRECTING and REPLACING GRAIL Announces Positive Validation Data for Its...
MENLO PARK, Calif. Ninth paragraph, first sentence of the release should read: In the group of more than 20 cancer types, the overall detection rate at 99.3 percent specificity was 55 percent...
View ArticleClik here to view.
Samyang Biopharm USA Expands and Strengthens its US Operations and Makes...
CAMBRIDGE, Mass. Samyang Biopharm USA, (us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Pharmaceuticals Corp. (https://samyangbiopharm.com/eng), today announced that it is...
View ArticleClik here to view.
雅诗兰黛公司以2019年乳腺癌防治运动团结全世界并带来希望
纽约 (美国商业资讯)–全世界每15秒就有一名女性被确诊患上乳腺癌1。正因为如此，自1992年以来，雅诗兰黛公司(The Estée Lauder Companies)一直致力于挽救生命——坚持履行公司乳腺癌防治运动(Breast Cancer...
View ArticleClik here to view.
Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4...
NORTH BRUNSWICK, N.J. Adlai Nortye Ltd. (“Adlai Nortye” or “the Company”), a global clinical-stage biopharmaceutical company dedicated to discovery, development and commercialization of new and...
View ArticleClik here to view.
MPEG LA宣布《核酸治疗药物》发表同行评议论文
丹佛 (美国商业资讯)–世界领先的技术许可证提供商MPEG LA 今天宣布，《核酸治疗药物》(Nucleic Acid Therapeutics) 2019年10月刊发表一篇有关MPEG LA专利Increscent Therapeutics™配体导向多负载寡聚核苷酸给药平台的同行评议的论文。 MPEG LA总裁兼首席执行官Larry Horn表示：“MPEG...
View Article